Reprogramming of Astrocytes to Neuronal-Like Cells in Spinal Cord Injury: A Systematic Review Publisher Pubmed



Alizadeh SD^{1, 2} ; Jalalifar MR^{1, 2} ; Ghodsi Z^{1, 3} ; Sadeghinaini M⁴ ; Malekzadeh H^{1, 3} ; Rahimi G^{5, 6, 7} ; Mojtabavi K^{1, 8} ; Shool S^{1, 9} ; Eskandari Z¹⁰ ; Masoomi R¹ ; Kiani S^{6, 7} ; Harrop J¹¹ ; Rahimimovaghar V^{1, 3, 12, 13} Show Affiliations
Source: Spinal Cord Published:2024

Abstract

Study design: A Systematic Review Objectives: To determine the therapeutic efficacy of in vivo reprogramming of astrocytes into neuronal-like cells in animal models of spinal cord injury (SCI). Methods: PRISMA 2020 guidelines were utilized, and search engines Medline, Web of Science, Scopus, and Embase until June 2023 were used. Studies that examined the effects of converting astrocytes into neuron-like cells with any vector in all animal models were included, while conversion from other cells except for spinal astrocytes, chemical mechanisms to provide SCI models, brain injury population, and conversion without in-vivo experience were excluded. The risk of bias was calculated independently. Results: 5302 manuscripts were initially identified and after eligibility assessment, 43 studies were included for full-text analysis. After final analysis, 13 manuscripts were included. All were graded as high-quality assessments. The transduction factors Sox2, Oct4, Klf4, fibroblast growth factor 4 (Fgf4) antibody, neurogenic differentiation 1 (Neurod1), zinc finger protein 521 (Zfp521), ginsenoside Rg1, and small molecules (LDN193189, CHIR99021, and DAPT) could effectively reprogramme astrocytes into neuron-like cells. The process was enhanced by p21-p53, or Notch signaling knockout, valproic acid, or chondroitin sulfate proteoglycan inhibitors. The type of mature neurons was both excitatory and inhibitory. Conclusion: Astrocyte reprogramming to neuronal-like cells in an animal model after SCI appears promising. The molecular and functional improvements after astrocyte reprogramming were demonstrated in vivo, and further investigation is required in this field. © The Author(s), under exclusive licence to International Spinal Cord Society 2024.